[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens

Roche rechnet für das Gesamtjahr 2026 mit einem Umsatzwachstum im mittleren einstelligen Bereich (CER) und peilt für den Kerngewinn je Aktie Wachstum im hohen einstelligen Bereich (CER) an. Zudem will das Unternehmen die Dividende in Schweizer Franken erneut erhöhen. Insgesamt ist das ein positiver Ausblick auf Wachstum und steigende Ausschüttungen.

Analysis

This reads more like a quality-duration confirmation than a re-rating catalyst. Mid-single-digit top-line plus high-single-digit EPS implies Roche is still getting operating leverage from mix, cost control, or both; that supports the stock as a defensive compounder, but it is not enough by itself to justify a sharp multiple expansion unless pipeline data in 2026 adds incremental growth optionality. The dividend signal matters because it narrows the bear case: management is telegraphing that cash conversion should cover both growth investment and capital returns, which reduces balance-sheet anxiety for long-only holders.

The main second-order effect is relative, not absolute. If Roche is credibly growing EPS faster than revenue, that puts pressure on peers with similar slow-growth profiles to defend capital returns, but the better trade is probably in relative valuation rather than outright beta. In a risk-off tape, RHHBY should screen as a lower-volatility pharma anchor versus higher-beta biotech and more cyclically exposed healthcare names; in a risk-on tape, it likely underperforms faster growers unless we get pipeline surprise.

The contrarian risk is that the market already expects exactly this: steady CER growth, modest dividend accretion, and no operational drama. If reported CHF results lag because of FX or if any core franchise slows, the stock can easily give back the initial positive reaction. The thesis is falsified if 2026 guidance is cut, if EPS growth relies on non-recurring cost actions, or if dividend growth is smaller than inflation, which would signal management is preserving flexibility rather than expressing confidence.

Key Decisions for Investors

• Hold or accumulate RHHBY only on weakness: use 3-5% pullbacks to build a defensive position with a 12-month horizon; thesis is cash-return support and downside resilience, not outsized upside.
• Prefer a relative-value long RHHBY / short higher-beta biotech or healthcare growth basket over an outright long; the spread should work if markets stay choppy and investors pay up for stability.
• Do not chase the name on the announcement alone; wait for 1-2 quarters of reported CHF EPS and FX translation before adding size, since a CER guide can overstate realized earnings momentum.
• Set a downside alert on any 2026 guide revision lower for sales or EPS, or a materially smaller CHF dividend hike; that would undermine the capital-return thesis and likely compress the multiple.